Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad144 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Ako Oiwa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Metabolism, Division of Internal Medicine, Shinshu University School of Medicine, Matsumoto 390-8621, Japan. Hauptthemen laut MEDLINE: Hyperkalemia, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Although adding spironolactone to renin-angiotensin system blockers reduces albuminuria in adults with chronic kidney disease and type 2 diabetes, it increases the risk of hyperkalemia.
Objective
To assess whether a lower dose of spironolactone (12.5 mg/d) reduces the risk of hyperkalemia while maintaining its effect on reducing albuminemia.
Design
Multicenter, open-label, randomized controlled trial.
Setting
This study was conducted from July 2016 to November 2020 in ambulatory care at 3 diabetes medical institutions in Japan. Patients We enrolled 130 Japanese adults with type 2 diabetes and albuminuria (≥30 mg/gCre), estimated glomerular filtration rate ≥30 mL/min/1.73 m2, and serum potassium level <5.0 mEq/L.
Interventions
The participants were randomly assigned to the spironolactone-administered and control groups. Main outcome measures Changes in urine albumin-to-creatinine ratio (UACR) from baseline over the 24-week interventional period.
Results
The spironolactone group showed a significant reduction in UACR from baseline (mean decrease, 103.47 ± 340.80 mg/gCre) compared with the control group, which showed an increased UACR (mean increase, 63.93 ± 310.14 mg/gCre; P = .0007, Wilcoxon rank-sum test and t test). Although the spironolactone group had a statistically significant increase in serum potassium levels, none of the participants had a potassium level ≥5.5 mEq/L at 24 weeks. Further, participants with a higher initial serum potassium level tended to have a smaller increase (estimate, −0.37, analysis of covariance).
Conclusions
Low-dose spironolactone administration reduced albuminuria without causing hyperkalemia. Spironolactone administration, the oldest known and most cost-effective mineralocorticoid receptor antagonist, at lower doses should be reconsidered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology and Metabolism, Division of Internal Medicine, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
- Takeda Internal Medicine Clinic, Azumino 399-8304, Japan.
- Miyamoto Internal Medicine Clinic, Matsumoto 390-0848, Japan.
- Center for Clinical Research, Shinshu University Hospital, Matsumoto 390-8621, Japan.
- Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Nakano 164-8530, Japan.
ORCID-Profile: Ako Oiwa
Zitieren
APA
Oiwa, A., Hiwatashi, D., Takeda, T., Miyamoto, T., Kawata, I., Koinuma, M., Yamazaki, M., & Komatsu, M. (2023). Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad144
Vancouver
Oiwa A, Hiwatashi D, Takeda T, Miyamoto T, Kawata I, Koinuma M, et al. Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad144
BibTeX
@article{Oiwa2023,
author = {Oiwa, Ako and Hiwatashi, Dai and Takeda, Teiji and Miyamoto, Takahide and Kawata, Iori and Koinuma, Masayoshi and Yamazaki, Masanori and Komatsu, Mitsuhisa},
title = {Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad144}
}
EUVIMED